Delayed Nasdaq 01:25:39 29/06/2024 am IST 5-day change 1st Jan Change
104.3 USD -2.05% Intraday chart for Illumina, Inc. -3.86% -25.04%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Would you like some more inflation? Our Logo
Illumina to Record $1.47 Goodwill Impairment Charge in Q2 After Grail Spin-Off MT
Illumina to take $1.47 billion impairment charge related to Grail in Q2 RE
Illumina Completes Grail Spin-Off Into Publicly Traded Entity, Holds Minority Stake MT
Grail bets big on flagship cancer test after spin-off from Illumina RE
Illumina, Inc.(NasdaqGS:ILMN) added to S&P 1000 CI
Illumina, Inc.(NasdaqGS:ILMN) dropped from S&P 500 Equal Weighted CI
Illumina, Inc.(NasdaqGS:ILMN) added to S&P 400 Health Care CI
Illumina, Inc.(NasdaqGS:ILMN) dropped from S&P 500 Value CI
Illumina, Inc.(NasdaqGS:ILMN) added to S&P 400 CI
Illumina, Inc.(NasdaqGS:ILMN) dropped from S&P 500 Ex-Financials, Real Estate, Utilities and Transportation Index CI
Illumina, Inc.(NasdaqGS:ILMN) dropped from S&P 500 CI
Illumina, Inc.(NasdaqGS:ILMN) dropped from S&P Global 1200 CI
Illumina, Inc.(NasdaqGS:ILMN) dropped from S&P 500 Health Care CI
Guggenheim Adjusts Price Target on Illumina to $138 From $159, Maintains Buy Rating MT
London follows US bullish trend Our Logo
RBC Cuts Price Target on Illumina to $249 From $253, Maintains Outperform Rating MT
Illumina Inc. Announces Launch of DRAGEN v4.3 CI
Evercore ISI Cuts Price Target on Illumina to $175 From $195 MT
Global markets live: ABB, Roche, Microsoft, Apple, Tesla... Our Logo
KKR & Co, CrowdStrike, GoDaddy to Join S&P 500 Index on June 24 MT
Futures slip on rate-cut jitters ahead of inflation data, Fed meeting RE
TD Cowen Adjusts Price Target on Illumina to $122 From $140 MT
Nephron Research Upgrades Illumina to Hold, Price Target at $100 MT
Global markets live: ASML, Intel, Microsoft, Tesla, J&J, Gitlab Our Logo
Chart Illumina, Inc.
More charts
Illumina, Inc. specializes in the development, manufacturing and marketing of integrated systems for the analysis of genetic variation and biological function. The group's products are for genomic research centers, pharmaceutical companies, university institutions, clinical research organizations, and biotechnology companies. Net sales break down by source of income as follows: - product sales (84.1%): tools and instruments for sequencing, genotyping, genetic expression, etc.; - sales of services (15.9%). Net sales are distributed geographically as follows: the United States (52.4%), Americas (3.6%), Europe (25.3%), Asia/Pacific/Middle East/Africa (10.2%) and China/Taiwan/Hong Kong (8.5%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
106.5 USD
Average target price
148.2 USD
Spread / Average Target
+39.25%
Consensus
  1. Stock Market
  2. Equities
  3. ILMN Stock
  4. News Illumina, Inc.
  5. Illumina Completes Grail Spin-Off Into Publicly Traded Entity, Holds Minority Stake